• Adrenocorticotropic hormone: an effective “natural” biologic therapy for acute gout? 

      Daoussis D., Bogdanos D.P., Dimitroulas T., Sakkas L., Andonopoulos A.P. (2020)
      Treatment of acute gout consists of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and steroids. However, the typical patient with gout has multiple comorbidities such as cardiovascular disease, hypertension, ...
    • Biologics in SAPHO syndrome: A systematic review 

      Daoussis D., Konstantopoulou G., Kraniotis P., Sakkas L., Liossis S.-N. (2019)
      Background: The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. ...
    • Clinical profile of severe asthmatics receiving biological treatment: see behind the scenes 

      Kotsiou O.S., Gourgoulianis K.I., Daniil Z. (2021)
      The clinical phenotyping of severe asthma could improve treatment outcomes, quality of life, morbidity, and mortality of asthma patients. The growing availability of rich clinical data could provide opportunities to address ...
    • SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics 

      Papaioannou A.I., Fouka E., Tzanakis N., Antoniou K., Samitas K., Zervas E., Kostikas K., Bartziokas K., Porpodis K., Papakosta D., Tzouvelekis A., Gerogianni I., Kotsiou O., Makris M., Rovina N., Vlachou G., Markatos M., Vittorakis S., Katsoulis K., Papanikolaou I., Afthinos A., Katsaounou P., Steiropoulos P., Latsios D., Dimakou K., Koukidou S., Hillas G., Tryfon S., Kallieri M., Georgopoulou A., Avarlis P., Bakakos P., Markopoulou K., Gaki E., Paspala A., Kyriakaki Z., Gourgoulianis K.I., Papiris S., Loukides S. (2022)
      Background: At the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics. Objective: To ...